Document Detail

Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
MedLine Citation:
PMID:  16502116     Owner:  NLM     Status:  MEDLINE    
It has been well established that hyperthyroidism leads to diminished bone mineral density (BMD), and that a previous history of hyperthyroidism remains a risk factor for fractures. However, little is known about how to manage the reduction in BMD caused by hyperthyroidism. The purpose of this study was to evaluate the efficacy of risedronate for the treatment of osteoporosis/osteopenia in patients with Graves' disease (GD). Of 34 Japanese male patients with newly diagnosed GD, 27 with osteoporosis/osteopenia were included in this study. They were randomly divided into two groups by therapeutic regimen. Group A consisted of 14 patients treated with an antithyroid drug and risedronate. Group B consisted of 13 patients treated with the same antithyroid drug only. We used dual-energy X-ray absorptiometry to measure BMD at the lumber spine, femoral neck, and distal radius at baseline, and at 6 and 12 months after the trial. Bone-specific alkaline phosphatase and urinary N-terminal telopeptide of type I collagen normalized by creatinine were significantly more reduced in group A than in group B after both 6 and 12 months. The percentage increases in BMD at the lumbar spine and distal radius were significantly greater in group A than in group B. These beneficial effects of risedronate for patients with osteoporosis/osteopenia caused by GD may lead to a reduced risk of future fractures. We thus conclude that risedronate should be considered for the treatment of decreased bone mass associated with GD.
Takafumi Majima; Yasato Komatsu; Kentaro Doi; Chieko Takagi; Michika Shigemoto; Atsushi Fukao; Takeshi Morimoto; Jerry Corners; Kazuwa Nakao
Related Documents :
8068446 - Effects of two different bisphosphonates on paget's disease of bone: ictp assessed.
15685456 - The effect of low-intensity pulsed ultrasound on callus maturation in tibial distractio...
10683086 - Preliminary results of the use of re-186-hedp for palliation of pain in patients with m...
8145096 - Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric crohn...
3174726 - Low molecular weight heparin prevention of post-operative deep vein thrombosis in vascu...
19251676 - Clinical efficacy of the microfracture technique for articular cartilage repair in the ...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of bone and mineral metabolism     Volume:  24     ISSN:  0914-8779     ISO Abbreviation:  J. Bone Miner. Metab.     Publication Date:  2006  
Date Detail:
Created Date:  2006-02-27     Completed Date:  2006-06-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9436705     Medline TA:  J Bone Miner Metab     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  105-13     Citation Subset:  IM    
Department of Endocrinology and Metabolism, Rakuwakai Otowa Hospital, Kyoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alkaline Phosphatase / metabolism
Bone Density
Bone Density Conservation Agents / therapeutic use
Bone Diseases, Metabolic
Bone and Bones / drug effects,  metabolism
Collagen Type I / chemistry
Etidronic Acid / analogs & derivatives*,  therapeutic use
Graves Disease / drug therapy*
Hyperthyroidism / drug therapy
Middle Aged
Models, Statistical
Osteoporosis / complications,  drug therapy*
Peptides / chemistry
Thyroid Hormones / metabolism
Time Factors
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Collagen Type I; 0/Peptides; 0/Thyroid Hormones; 0/collagen type I trimeric cross-linked peptide; 105462-24-6/risedronic acid; 2809-21-4/Etidronic Acid; EC Phosphatase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Factors associated with mortality following hip fracture in Japan.
Next Document:  Secondary hyperparathyroidism as a palpable intrathyroid parathyroid gland in a patient with hypopho...